Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to
evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes
of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The
study is sponsored by AstraZeneca.